You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Chemiluminescent Assay and Device for Monitoring Vascular Endogenous Nitric Oxide
SBC: BIOLUM SCIENCES LLC Topic: 400Project Summary A Chemiluminescent Assay and Device for Monitoring Vascular Endogenous Nitric Oxide This STTR Phase I project aims to establish the feasibility of a novel chemiluminescent assay for the detection of nitric oxide in blood. Phase II will aim to use this assay in a point-of-care device to measure vascular endogenous nitric oxide (VeNO) from a finger-prick of blood for ultimate deploym ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A Cloud based Application for the Joint Analysis of Multiple Big Data Types
SBC: MathNimbus Inc Topic: 400Project Summary Technology advances now enable the cost effective acquisition of Kandgt distinct data types from a common set of N bio samples where i the kth data type is represented by a data matrix with columns containing Pk measurements in N samples for k K and ii at least one of the data types is big i e Pk is much bigger than N for some k The rapid accumulation of such mult ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin
SBC: VAXIN INC. Topic: N/ADESCRIPTION (provided by applicant): Propionibacterium acnes (P. acnes) is most notably recognized for its role in acne vulgaris, the most common skin disease, affecting 85-100% of the population at some point in their lives. Current treatments for vulgari s acne using isotretinoin (13-cis-retinoic acid) or antibiotics can have many undesirable effects, including depression, teratogenicity, hormon ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Acute-infarct selective cardiac MRI contrast agent
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Reliable diagnostic differentiation between acute and chronic myocardial infarcts would be of great benefit for cardiac surgeons and interventional cardiologists. Such differentiation could be used to make decisions about which vessels and in what order would be reopened or bypassed. MRI is an intrinsically noninvasive diagnostic tool and the Delayed Enhancemen ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Acute-infarct selective cardiac MRI contrast agent
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: NHLBIDESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Adenovirus vectored vaccines for Alzheimer's disease
SBC: VAXIN INC. Topic: N/ADESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels. Increasing lines of evidence support the notion that Aa and its precursor (APP) play pathogenetic roles i ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
A device containing an immobilized chelator to remove aluminum from total parente
SBC: ALKYMOS, INC Topic: NICHDDESCRIPTION (provided by applicant): A high percentage of the ~ 500,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common contam ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
A device containing immobilized chelator to remove aluminum from TPN solutions
SBC: ALKYMOS, INC Topic: N/ADESCRIPTION (provided by applicant): A high percentage of the ~ 470,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common conta ...
STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
A Device to Inhibit Heterotopic Ossification
SBC: IN SITU THERAPEUTIC SOLUTIONS, INC. Topic: NIAMSPROJECT SUMMARY ABSTRACT Heterotopic ossificationHOis defined by bone formation in soft tissue and is a frequent debilitating complication of surgical procedures required by musculoskeletal and neurological injuriesUnfortunatelyit is not possible to accurately predict which patients will develop symptomatic HOwhich is characterized by pain and impaired functionThe current prophylactic standard of ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
ADF, novel cytokine PPAR-gamma regulator from fat cells
SBC: GENETEX, INC. Topic: N/ADESCRIPTION (Scanned from the Applicant's Abstract): Obesity is a major risk factor for diabetes mellitus (type 2; NIDDM). Fat cells secrete both diabetes promoting molecules (fatty acids; TNF-alpha) and at least one molecule that may be antidiabetic (leptin). We have partially purified a new protein (cytokine) which is also secreted by mature adipocytes, Adipocyte Diffe ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health